Literature DB >> 28120172

Vernal shield ulcers treated with frequently installed topical cyclosporine 0.05% eyedrops.

Tim Westland1,2, Eliza K Patryn3, Carla P Nieuwendaal4, Ivanka J E van der Meulen4, Maarten P Mourits3,4, Ruth Lapid-Gortzak4,5.   

Abstract

PURPOSE: To report on the beneficial results of an intense regimen of 0.05% cyclosporine eye drops, eight times a day in patients with therapy resistant vernal shield ulcers.
METHODS: Case cohort of four eyes of three male children with vernal keratoconjunctivitis complicated by shield ulcers, who were treated with frequent cyclosporine 0.05% eye drops and observed for up to 5 years.
RESULTS: Quick resolution of the shield ulcers and complete re-epithelialization within 14-25 days was observed after adding intensive treatment with cyclosporine 0.05% to regular anti-inflammatory, histamine blocking, and surgical therapy. In one patient, additional scraping of the bottom of the ulcer was needed.
CONCLUSIONS: In patients with vernal shield ulcers, frequent installation of low-concentration cyclosporine eye drops seems to have a promising therapeutical value.

Entities:  

Keywords:  Allergy; Cyclosporine A; Immunomodulation; Shield ulcer; Vernal catarrh; Vernal keratoconjunctivitis

Mesh:

Substances:

Year:  2017        PMID: 28120172     DOI: 10.1007/s10792-016-0424-z

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  18 in total

1.  Penicillium keratitis in vernal Keratoconjunctivitis.

Authors:  Ritu Arora; Seema Gupta; Usha K Raina; Dinesh K Mehta; Mukesh Taneja
Journal:  Indian J Ophthalmol       Date:  2002-09       Impact factor: 1.848

2.  Topical cyclosporine in the management of shield ulcers.

Authors:  Altug Cetinkaya; Yonca Aydin Akova; Dilek Dursun; Aysel Pelit
Journal:  Cornea       Date:  2004-03       Impact factor: 2.651

3.  Combined therapy for vernal shield ulcer.

Authors:  Sunil Kumar
Journal:  Clin Exp Optom       Date:  2008-01       Impact factor: 2.742

4.  Videokeratography findings in children with vernal keratoconjunctivitis versus those of healthy children.

Authors:  Ruth Lapid-Gortzak; Shirley Rosen; Shimon Weitzman; Tova Lifshitz
Journal:  Ophthalmology       Date:  2002-11       Impact factor: 12.079

5.  Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup.

Authors:  S Bonini; S Bonini; A Lambiase; S Marchi; P Pasqualetti; O Zuccaro; P Rama; L Magrini; T Juhas; M G Bucci
Journal:  Ophthalmology       Date:  2000-06       Impact factor: 12.079

6.  Ocular effects of long term use of topical steroids among children and adolescents with vernal keratoconjunctivitis: a prospective observational study.

Authors:  Radhakrishna Mandal; Prasenjit Maiti; Nirmal Kumar Sasmal; Nirmalya Sinha; Aninda Gupta; Kali Sankar Das; Mukul Chandra Biswas
Journal:  J Indian Med Assoc       Date:  2011-10

Review 7.  Aspergillus keratitis in vernal shield ulcer--a case report and review.

Authors:  Vandana Jain; Kanupriya Mhatre; Akshay G Nair; Debraj Shome; Sundaram Natarajan
Journal:  Int Ophthalmol       Date:  2010-02-03       Impact factor: 2.031

8.  Surgical management of corneal plaques in vernal keratoconjunctivitis: a clinicopathologic study.

Authors:  Abraham Solomon; Ehud Zamir; Shmuel Levartovsky; Joseph Frucht-Pery
Journal:  Cornea       Date:  2004-08       Impact factor: 2.651

9.  Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.

Authors:  Neri Pucci; Elio Novembre; Antonella Cianferoni; Enrico Lombardi; Roberto Bernardini; Roberto Caputo; Luciana Campa; Alberto Vierucci
Journal:  Ann Allergy Asthma Immunol       Date:  2002-09       Impact factor: 6.347

Review 10.  Vernal keratoconjunctivitis: pathogenesis and treatment.

Authors:  Andrea Leonardi
Journal:  Prog Retin Eye Res       Date:  2002-05       Impact factor: 21.198

View more
  1 in total

Review 1.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.